10598418 - GAU: 1641

Attorney Docket No. 100719-690 KGB

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Michael PAWLAK, et al

SERIAL NO. : To Be Assigned

CUSTOMER NO. : 27384

FILED : Herewith

FOR : ANALYTICAL PLATFORM AND METHOD FOR GENERATING

PROTEIN EXPRESSION PROFILES OF CELL POPULATIONS

ART UNIT : To Be Assigned

EXAMINER : To Be Assigned

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants respectfully request that the Examiner consider the references listed on the attached Form PTO/SB/08.

# I. Timeliness, Fees and Certifications in lieu of Fees

This information disclosure statement is being filed within three months of the filing date of the application, or within three months of entry into the national stage, or before the mailing of a first Office Action on the merits. Pursuant to 37 CFR § 1.97(b), consideration of this information disclosure statement does not require a fee or a statement under 37 CFR § 1.97(e). However, should the Assistant Commissioner determine that a fee is, in fact, due, the Assistant Commissioner is hereby authorized to charge the fee to Deposit Account No. 14-1263.

10598418 - GAU: 1641

# II. Copies of Listed References

This application is a PCT national stage application, all references listed on the attached Form PTO/SB/08 were cited in the international search report, that both the international search report and the copies of the references listed on the attached Form PTO/SB/08 are in this national stage file. Therefore, copies of the references listed on the attached Form PTO/SB/08 are not now being supplied.

# III. Concise Statement of Relevance

All references listed on the attached Form PTO/SB/08 are referred to in the international search report, and a copy of that search report, which indicates the degree of relevance found by the International Search Authority, is attached.

Consideration of the foregoing in relation to this application is respectfully requested.

Respectfully submitted,

NORRIS MCLAUGHLIN & MARCUS, P.A.

By \_\_

Kurt G. Briscoe Attorney for Applicant(s) Reg. No. 33,141 875 Third Avenue - 18<sup>th</sup> Floor New York, New York 10022 Phone: (212) 808-0700

Fax: (212) 808-0844

10598438888 (GAU: 1641
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of a collection of information unless it contains a unless of the contains a unless o

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number			
INFORMATION BIOOLOGUES	Filing Date			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor	Micha	ael PAWLAK et al	
	Art Unit			
	Examiner Name			
	Attorney Docket Numb	er	100717-690 KGB5,822	

					U.S.I	PATENTS				
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue C	)ate	of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	5822472	A	1998-10	)-13	Novartis Corpo	pration			
	2	6078705	А	2000-06	S-20	Novartis AG				
	3	6287768	B1	2001-09	J-11	Clontech Labor	ratories			
	4									
If you wis	h to ac	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.			
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	of cited Document		Relev	s,Columns,Lines where vant Passages or Relevant es Appear	
	1	20030148542	A1	2003-08	i-07	Zeptosens AG				
If you wish to add additional U.S. Published Application citation information please click the Add button.										
				FOREIG	SN PAT	ENT DOCUM	ENTS			
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date  Name of Patentee of Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	

				Appli	cation	Number		105	598418 - GAU: 1	641
			Filing	Date						
STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)		First I	Named	Inventor	Micha	ael PAWLAK et al				
		Art U	nit					- 1		
		Exam	niner N	ame		1				
				Attorr	ney Do	cket Numb	er	100717-690 KGB5,822		
	1	0184197	wo		A	2001-11-0		Edgelight Biosciences - Optical Crosslinks		
	2	0220873	wo		А	2002-03-	14 2	09/30/200 Zeptosens AG	9	
	3	04023143	wo		A	2004-03-	18 2	Zeptosens AG		
If you wis	h to a	l dd additional Foreid	n Patent Do	ocument	L citatio	l n information	on ple:	ase click the Add buttor	<u> </u> 1	
you		aa aaamonan oo				ERATURE			<u> </u>	
		Include name of t						ne article (when appropri	riate) title of the item	
Examiner Initials*	Cite No		journal, seri	al, symp	osium	, catalog, e		ite, pages(s), volume-is		<b>T</b> 5
		DINGS IS OF								
***************************************	occoponomo	waveguides", Sens						d on luminescence excita o. 38-39	tion by planar	***************************************
		DAMINE Motal:	"Eupotional in	mobilizo	tion of l	hiomombron	o frago	nonte en planer weveguid	as for the investigation of	
000000000000000000000000000000000000000	PAWLAK, M. et al: "Functional immobilization of biomembrane fragments on planar waveguides for the investigation of side-directed ligand binding by surface confined fluorescence", Faraday Discussions (1998) pages 273-288, No. 111,									
		England								
		RIJIZ-TAVLOR I	A et al: "Mon	olavers c	of deriva	atized noly/l	-lveine	Larafted poly(ethylene alv	vcol) on metal oxides as a	
***************************************		class of biomolecul	ar interfaces",	Procees	<del>lings of</del>	the National	Acade	my of Sciences of USA (2		
		Vol. 98, No. 3, Natio	onal Academy	of Scier	ice, Wa	shington, U	S.			
000000000000000000000000000000000000000	4	PAWLAK, M. et al:   protein analysis , P					nigh pe	rformance microarray plat	form for low abundance	***************************************
		, ,	•	,ı <u>3</u>		,				
If you wis	h to a	dd additional non-p	atent literatu	ıre docu	ment c	citation info	matio	n please click the Add b	outton	
				EX	AMIN	ER SIGNA	TURE			
Examine	Signa	ature /Ann l	_am/					Date Considered	09/30/2009	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.L./

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE	Application Number Filing Date		10598418 - GAU: 164	
	First Named Inventor Micha		nael PAWLAK et al	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit			
( Not for submission under 37 CFR 1.99)	Examiner Name			
	Attorney Docket Numb	er	100717-690 KGB5,822	

<sup>1</sup> See Kind Codes of USPTO Patent Documents at <a href="www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number 10598418 - GAU: 1641 Filing Date First Named Inventor Michael PAWLAK et al Art Unit Examiner Name Attorney Docket Number 100717-690 KGB5,822

	CERTIFICATION STATEMENT						
Plea	Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):						
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).						
OR	OR						
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).						
	See attached certification statement.						
	Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.						
	None						
As	SIGNATURE  A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the						
	form of the signature.						
Sigr	nature	Date (YYYY-MM-DD)					
Nan	ne/Print	Registration Number					

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** 

10598418 - GAU: 1641

# **Privacy Act Statement**

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
  - 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.